Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients

被引:1
|
作者
Tortosa-Carreres, Jordi [1 ,2 ,3 ]
Cubas-Nunez, Laura [3 ]
Quiroga-Varela, Ana [4 ,5 ]
Castillo-Villalba, Jessica [3 ,4 ,5 ]
Ramio-Torrenta, Lluis [4 ,5 ,6 ,7 ]
Piqueras, Monica [1 ,2 ,8 ]
Gasque-Rubio, Raquel [2 ,3 ]
Quintanilla-Bordas, Carlos [3 ,9 ]
Sanz, Maria Teresa [10 ]
Lucas, Celia [11 ]
Huertas-Pons, Joana Maria [4 ,5 ]
Miguela, Albert [4 ,5 ]
Casanova, Bonaventura [3 ,9 ]
Laiz-Marro, Begona [1 ]
Perez-Miralles, Francisco Carlos [3 ,9 ]
机构
[1] La Fe Univ & Polytech Hosp, Lab Dept, Valencia 46026, Spain
[2] Univ Valencia, Med Dept, Valencia 46010, Spain
[3] Hlth Res Inst La Fe IISLAFE, Neuroimmunol Unit, Valencia, Spain
[4] Dr Josep Trueta Univ Hosp, Neurol Dept, Girona Neuroimmumol & Multiple Sclerosis Unit, Girona, Spain
[5] Santa Caterina Hosp, Girona, Spain
[6] Girona Biomed Res Inst IDIBGI, Neurodegenerat & Neuroinflammat Res Grp, Girona, Spain
[7] Univ Girona, Med Sci Dept, Girona, Spain
[8] Hlth Res Inst La Fe IISLAFE, Resp Infect, Valencia, Spain
[9] La Fe Univ & Polytech Hosp, Neurol Dept, Valencia 46026, Spain
[10] Univ Valencia, Dept Didact Math, Valencia, Spain
[11] La Fe Univ & Polytech Hosp, Comp Syst, Valencia 46026, Spain
关键词
Multiple sclerosis; Prognosis; Free kappa light chains; Therapeutic failure;
D O I
10.1016/j.msard.2024.105734
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Our objective was to explore various biomarkers for predicting suboptimal responses to diseasemodifying treatments (DMTs) in patients with MS (pwMS).<br /> Methods: We conducted a longitudinal, bicentric study with pwMS stratified based on their DMTs responses. Treatment failure (TF) was defined as the onset of a second relapse, presence of two or more T2 new lesions, or disability progression independent of relapse during the follow-up period. We evaluated intrathecal synthesis (ITS) of IgG and IgM using OCB, linear indices, and Reibergrams. Free kappa light chains ITS was assessed using the linear index (FKLCi). NfL and GFAP in serum and CSF, and CHI3L1 in CSF were quantified. Quantitative variables were dichotomized based on the third quartile. Predictive efficacy was assessed through bivariate and multivariate analyses, adjusting for age, sex, EDSS, acute inflammatory activity (AI) -defined as the onset of a relapse or gadolinium-enhancing lesions within a 90-day window of lumbar puncture-, treatment modality, study center, and time from disease onset to treatment initiation. In case of collinearity, multiple models were generated or confounding variables were excluded if collinearity existed between them and the biomarker. The same methodology was used to investigate the predictive potential of various combinations of two biomarkers, based on whether any of them tested positive or exceeded the third quartile.<br /> Results: A total of 137 pwMS were included. FKLCi showed no differences based on AI, no correlation with EDSS and was significantly higher in pwMS with TF (p = 0.008). FKLCi>130 was associated with TF in bivariate analysis (Log-Rank p = 0.004). Due to collinearity between age and EDSS, two different models were generated with each of them and the rest of the confounding variables, in which FKLCi>130 showed a Hazard Ratio (HR) of 2.69 (CI: 1.35-5.4) and 2.67 (CI: 1.32-5.4), respectively. The combination of either FKLC or sNfL exceeding the third quartile was also significant in bivariate (Log-Rank p = 0.04) and multivariate (HR=3.1 (CI: 1.5-6.5)) analyses. However, when analyzed independently, sNfL did not show significance, and FKLCi mirrored the pattern obtained in the previous model (HR: 3.04; CI: 1.51-6.1). Treatment with highefficacy DMTs emerged as a protective factor in all models.<br /> Discussion: Our analysis and the fact that FKLCi is independent of EDSS and AI suggest that it might be a valuable parameter for discriminating aggressive phenotypes. We propose implementing high-efficacy drugs in pwMS with elevated FKLCi.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis
    Cross, Anne H.
    Gelfand, Jeffrey M.
    Thebault, Simon
    Bennett, Jeffrey L.
    von Buedingen, H. Christian
    Cameron, Briana
    Carruthers, Robert
    Edwards, Keith
    Fallis, Robert
    Gerstein, Rachel
    Giacomini, Paul S.
    Greenberg, Benjamin
    Hafler, David A.
    Ionete, Carolina
    Kaunzner, Ulrike W.
    Kodama, Lay
    Lock, Christopher
    Longbrake, Erin E.
    Musch, Bruno
    Pardo, Gabriel
    Piehl, Fredrik
    Weber, Martin S.
    Yuen, Steven
    Ziemssen, Tjalf
    Bose, Gauruv
    Freedman, Mark S.
    Anania, Veronica G.
    Ramesh, Akshaya
    Winger, Ryan C.
    Jia, Xiaoming
    Herman, Ann
    Harp, Christopher
    Bar-Or, Amit
    JAMA NEUROLOGY, 2024, 81 (04) : 373 - 383
  • [2] Identification of Biomarkers in Cerebrospinal Fluid and Serum of Multiple Sclerosis Patients by Immunoproteomics Approach
    Colomba, Paolo
    Fontana, Simona
    Salemi, Giuseppe
    Barranca, Marilisa
    Lo Sicco, Claudia
    Mazzola, Maria Antonietta
    Ragonese, Paolo
    Savettieri, Giovanni
    De Leo, Giacomo
    Alessandro, Riccardo
    Duro, Giovanni
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (12): : 23269 - 23282
  • [3] Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis
    Sellebjerg, F
    Christiansen, M
    Nielsen, PM
    Frederiksen, JL
    MULTIPLE SCLEROSIS, 1998, 4 (06): : 475 - 479
  • [4] Serum and Cerebrospinal Fluid Cytokine Biomarkers for Diagnosis of Multiple Sclerosis
    Martynova, Ekaterina
    Goyal, Mehendi
    Johri, Shikhar
    Kumar, Vinay
    Khaibullin, Timur
    Rizvanov, Albert A.
    Verma, Subhash
    Khaiboullina, Svetlana F.
    Baranwal, Manoj
    MEDIATORS OF INFLAMMATION, 2020, 2020
  • [5] Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients
    Fitzner, Brit
    Hecker, Michael
    Zettl, Uwe Klaus
    AUTOIMMUNITY REVIEWS, 2015, 14 (10) : 903 - 913
  • [6] Cerebrospinal fluid biomarkers in multiple sclerosis
    Tumani, Hayrettin
    Hartung, Hans-Peter
    Hemmer, Bernhard
    Teunissen, Charlotte
    Deisenhammer, Florian
    Giovannoni, Gavin
    Zettl, Uwe K.
    NEUROBIOLOGY OF DISEASE, 2009, 35 (02) : 117 - 127
  • [7] Multiple sclerosis cerebrospinal fluid biomarkers
    Giovannoni, Gavin
    DISEASE MARKERS, 2006, 22 (04) : 187 - 196
  • [8] Fluid biomarkers for disease activity in multiple sclerosis
    Zetterberg, Henrik
    Teunissen, Charlotte
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : 1660 - 1661
  • [9] Cerebrospinal Fluid Biomarkers of Multiple Sclerosis Patients in Relapse and Remission
    Orbach, Rotem
    Gurevich, Michael
    Achiron, Anat
    NEUROLOGY, 2011, 76 (09) : A375 - A375
  • [10] Biomarkers of disease activity in multiple sclerosis patients treated with immunomodulatory agents
    Hesse, Dan
    Krakauer, Martin
    Lund, Henrik
    Langkilde, Annika
    Sellebjerg, Finn
    Sorensen, Per Soelberg
    MULTIPLE SCLEROSIS, 2008, 14 : S281 - S281